KL
NKGN

KIM LLC’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

KIM LLC’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-300,000
Closed -$3.1M – 422
2023
Q2 		$3.1M Sell
300,000
-460,200
-61% -$4.71M 0.27% 85
2023
Q1 		$7.7M Buy
760,200
+300,000
+65% +$3.03M 0.54% 42
2022
Q4 		$4.58M Hold
460,200
– – 0.25% 81
2022
Q3 		$4.49M Hold
460,200
– – 0.21% 105
2022
Q2 		$4.47M Buy
+460,200
New +$4.48M 0.21% 107

Other funds holding NKGN

MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.56% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

KIM LLC's NKGN Position: Q3 2023 in Review

KIM LLC sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2023, closing a stake of 300,000 shares — an estimated $3.1M sold.

KIM LLC first reported a position in NKGN in Q2 2022 and held it in 5 quarters. The position peaked at $7.7M in Q1 2023. 13 funds tracked by Wall St. Rank hold NKGN as of Q3 2023.

  • KIM LLC reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • KIM LLC sold 300,000 NKGen Biotech, Inc. Common Stock shares in Q3 2023, an estimated $3.1M.
  • KIM LLC first reported a position in NKGen Biotech, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • KIM LLC's NKGen Biotech, Inc. Common Stock position peaked at $7.7M in Q1 2023.
  • 13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2023.

Based on KIM LLC's 13F filing for Q3 2023, filed 13 Nov 2023.